Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D1414 | doxycycline

Molecular Formula C22H24N2O8
Molecular Weight 444.4
Structure
State solid
Clearance The excretion of doxycycline by the kidney is about 40% over 72 hours in individuals with normal kidney function (creatinine clearance approximately 75 mL/min). This rate may fall as low as 1-5% over 72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Some clinical studies have shown no major difference in serum half-life of doxycycline (range 18-22 hours) in patients with normal and severely impaired renal function. Hemodialysis does not affect serum half-life of doxycycline [FDA label].
Volume of distribution Doxycycline diffuses readily into most body tissues, fluid and/or cavities and the volume of distribution has been measured as 0.7 L/kg [F3052].
Route of elimination Mainly the urine and feces as active and unchanged drug [FDA label]. Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% can be accounted for in the feces [F3055].
Protein binding >90% [FDA label], [F3055].
Half life 16.33 hr (± 4.53 sd) [FDA label].
Absorption Tetracyclines, such as doxycycline, are readily absorbed and are bound to plasma proteins by varying degrees. Doxycycline is almost completely absorbed after oral administration. This drug is highly lipid soluble and has a low affinity for calcium binding [FDA label]. Absorption is not significantly affected by the concomitant ingestion of food or milk [F3052]. Peak serum levels of approximately 2.6 mcg/ml are reached at 2 hours following a 200 mg tablet oral dose [F3052].
Trade names Doryx, Doxyhexal, Doxylin
Description broad-spectrum antibiotic; second-generation tetracycline; derived from oxytetracycline

J

A

J01AA20 Combinations of tetracyclines


[J01AA] Tetracyclines


[J01A] TETRACYCLINES


[J01] ANTIBACTERIALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

J01AA02 Doxycycline


[J01AA] Tetracyclines


[J01A] TETRACYCLINES


[J01] ANTIBACTERIALS FOR SYSTEMIC USE


[J] Antiinfectives for systemic use

A01AB22 Doxycycline


[A01AB] Antiinfectives and antiseptics for local oral treatment


[A01A] STOMATOLOGICAL PREPARATIONS


[A01] STOMATOLOGICAL PREPARATIONS


[A] Alimentary tract and metabolism

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX ASSEMBLY 15 µg/ml 6 days 143B osteosarcoma cells BN PAGE analysis, In-gel complex I activity and western blotting inhibitor 285
MITOCHONDRIAL PROTEIN TRANSLATION 143B osteosarcoma cells inhibitor 285

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 117 companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (74.36%): Harmful if swallowed [Warning Acute toxicity, oral]


H315 (72.65%): Causes skin irritation [Warning Skin corrosion/irritation]


H317 (10.26%): May cause an allergic skin reaction [Warning Sensitization, Skin]


H319 (72.65%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (72.65%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


H360 (26.5%): May damage fertility or the unborn child [Danger Reproductive toxicity]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P261, P264, P270, P271, P272, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Warning

Aggregated GHS information provided by 96 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 3 of 96 companies. For more detailed information, please visit ECHA C&L website


Of the 3 notification(s) provided by 93 of 96 companies with hazard statement code(s):


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


H312 (55.91%): Harmful in contact with skin [Warning Acute toxicity, dermal]


H315 (59.14%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (59.14%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H332 (55.91%): Harmful if inhaled [Warning Acute toxicity, inhalation]


H335 (59.14%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Warning

Aggregated GHS information provided by 2 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 intravenous 241mg/kg (241mg/kg) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 305, 1979.
mouse LD50 oral 1870mg/kg (1870mg/kg) Giornale Italiano di Chemioterapia. Italian Journal of Chemotherapy. Vol. 17, Pg. 276, 1970.
dog LD50 intravenous > 100mg/kg (100mg/kg) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 305, 1979.
mouse LD50 intraperitoneal 410mg/kg (410mg/kg) Giornale Italiano di Chemioterapia. Italian Journal of Chemotherapy. Vol. 17, Pg. 276, 1970.
rat LD50 oral > 2gm/kg (2000mg/kg) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 305, 1979.
rat LD50 intraperitoneal 378mg/kg (378mg/kg) Therapie. Vol. 23, Pg. 575, 1968.
women TDLo oral 68mg/kg/24D-I (68mg/kg) musculoskeletal: joints Postgraduate Medical Journal. Vol. 67, Pg. 313, 1991.
women TDLo oral 68mg/kg/24D-I (68mg/kg) Postgraduate Medical Journal. Vol. 67, Pg. 313, 1991.
rat LD50 intravenous 228mg/kg (228mg/kg) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 305, 1979.
dog LD50 oral > 500mg/kg (500mg/kg) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 305, 1979.


  • DrugBank DB00254
    CAS Number 564-25-0, 94088-85-4, 24390-14-5
    PubChem Compound 54671203